Millennium Pharmaceuticals Q3-Zahlen - 500 Beiträge pro Seite
eröffnet am 17.10.00 22:35:38 von
neuester Beitrag 18.10.00 17:55:14 von
neuester Beitrag 18.10.00 17:55:14 von
Beiträge: 17
ID: 272.951
ID: 272.951
Aufrufe heute: 0
Gesamt: 1.563
Gesamt: 1.563
Aktive User: 0
ISIN: US5999021034 · WKN: 900625
Feedback
morgen kommen vorbörslich die 3. Quartalszahlen, hat jemand Informationen, wie die Flüsterschätzungen liegen ?
thanx B1B2
thanx B1B2
WHISPER NUMBER N/A
MLNM fällt nachbörslich auf 67$ 
Millenium Pharmaceuticals weitet seinen Netto-Verlust aus:
Gegenüber dem letzten Jahr hat sich der Netto-Verlust von 0.03$ auf 0.13$ pro Aktie mehr als vervierfacht!!!
Gegenüber dem letzten Jahr hat sich der Netto-Verlust von 0.03$ auf 0.13$ pro Aktie mehr als vervierfacht!!!
durchschnittlich erwartet: - 0,11 $
Trading Spotlight
@Millenia
weißt du mehr als andere? Die Zahlen kommen erst morgen vorbörslich!!
bitte Quellenangabe, danke
weißt du mehr als andere? Die Zahlen kommen erst morgen vorbörslich!!
bitte Quellenangabe, danke
Was für ein Jammer!!!
Solch eine schlechte Informationslage ist ja zum Heulen!!!
Na ja,also vielleicht hast du schon einmal von der amerikanischen Finanzsite http://www.bigcharts.com gehört?
Wenn nicht,als erfahrener Anleger ein Schönheitsfehler,aber schau dort mal unter dem Kürzel MLNM für Millenium Pharmaceuticals nach!
Dort siehst du dan unter den wichtigsten News,das dieses Biotech-Unternehmen schon seine Quartalszahlen für das 3. Quartal gemeldet hat!
Solch eine schlechte Informationslage ist ja zum Heulen!!!
Na ja,also vielleicht hast du schon einmal von der amerikanischen Finanzsite http://www.bigcharts.com gehört?
Wenn nicht,als erfahrener Anleger ein Schönheitsfehler,aber schau dort mal unter dem Kürzel MLNM für Millenium Pharmaceuticals nach!
Dort siehst du dan unter den wichtigsten News,das dieses Biotech-Unternehmen schon seine Quartalszahlen für das 3. Quartal gemeldet hat!
ok, danke,
habe es nun auch gefunden...
Tuesday October 17, 5:13 pm Eastern Time
Press Release
SOURCE: Millennium Pharmaceuticals, Inc.
Millennium Reports Third Quarter 2000 Financial Results
-- Exercise of Over-Allotment from Equity Offering Brings Cash Balance to Over $1.4 Billion --
CAMBRIDGE, Mass., Oct. 17 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today reported consolidated financial results for the three and nine months ended September 30, 2000.
(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
Revenue for the quarter ended September 30, 2000 was $49.8 million compared to $40.3 million for the same period in 1999. This is the first quarter that the company recognized revenue from its ground-breaking alliance with Aventis Pharma. Millennium`s corporate alliances provide the Company with substantial revenues, enabling technologies and rights that allow the Company to build upon its proprietary drug discovery and development product pipeline and technology base.
Expenditures for research and development for the quarter ended September 30, 2000 were $68.8 million versus $38.4 million for the same period in 1999. The increase is primarily due to Millennium`s investments in all aspects of research and development necessary to execute its strategy of becoming a major biopharmaceutical company. These include investments in its science and technology platform, as well as investments in development candidates and the preclinical pipeline, which were not in place in the prior period.
General and administrative expenses for the quarter ended September 30, 2000 were $12.4 million versus $8.3 million for the same period in 1999. This increase is due to the expansion of operations and infrastructure necessary to support growth at all levels of Millennium`s business.
Net operating loss, before amortization charges and debt conversion expenses, for the quarter ended September 30, 2000 was $25.9 million or $0.13 per basic and diluted share, compared to net operating loss, before amortization charges and debt conversion expenses, of $3.8 million or $0.03 per basic and diluted share for the same period in 1999. In addition, Millennium recorded amortization charges of $14.5 million for the quarter resulting from strategic acquisitions. During the quarter, Millennium paid an aggregate of $49.3 million in cash to the holders of Millennium`s convertible notes in order to induce the conversion of their notes into Millennium common stock. These conversions resulted in the retirement of $275.1 million of outstanding principal of Millennium convertible notes, and the issuance of approximately 6.5 million shares of Millennium common stock.
As of September 30, 2000, Millennium had approximately $679 million in cash, cash equivalents and marketable securities. In October, the Company raised an additional $767 million in a public offering of its common stock (including the underwriters` exercise of their over-allotment option), bringing the total cash balance as of October 17, 2000 to over $1.4 billion.
``We are on track to achieve our corporate goals for 2000, including developing the industry`s broadest emerging clinical and preclinical pipeline, enhancing productivity by addressing key bottlenecks in the drug discovery and development process, and building a world class senior leadership team,`` said Mark Levin, chief executive officer of Millennium. ``With over $1.4 billion in cash, Millennium has the resources to continue to invest in our pipeline and to enhance our downstream capabilities, moving us closer to our goal of building the biopharmaceutical company of the future.``
Third Quarter Company Highlights:
-- Stock Changes:
* The Millennium Board of Directors approved a two-for-one stock split
of its common shares effected in the form of a stock dividend.
Stockholders of record on September 27, 2000, were entitled to one
additional share of common stock for each share held on that date.
The dividend distribution date was October 4, 2000.
* Millennium announced (and completed in October 2000) a public offering
of its common stock which resulted in the Company raising $767
million. The proceeds will be used for working capital and other
corporate purposes including financing the Company`s growth,
accelerating the expansion of its technology platform and developing
products.
-- Mergers and Acquisitions:
* Millennium completed its acquisition of Cambridge Discovery Chemistry
Limited (CDC) in Cambridge, UK. CDC, renamed Millennium
Pharmaceuticals
Limited, provides the Company with the critical mass in medicinal and
computational chemistry necessary to expand the Company`s global
capacity and significantly accelerate its downstream drug discovery
efforts.
-- Senior Hires:
* Millennium announced the appointment of James A. Nash as senior vice
president of worldwide manufacturing, a newly-created position. Prior
to joining the Company, Mr. Nash was vice president of manufacturing
worldwide at Monsanto/Searle. With more than 20 years of experience
in the pharmaceutical industry, he is working with the Company`s
senior leadership team to develop and expand both small molecule and
biotherapeutic manufacturing capabilities needed to build the
biopharmaceutical company of the future.
* Michael W. Spellman, Ph.D., joined the Company as vice president of
quality assurance and quality control. Most recently, Dr. Spellman
was vice president, preclinical development at Coulter Pharmaceutical.
He brings to the Company more than 16 years experience in
biopharmaceutical drug development.
* Steven Gilman, Ph.D., joined the Company as vice president,
inflammation. Dr. Gilman brings over 20 years of experience in the
pharmaceutical and biotechnology industries, including providing
expertise for the strategic direction of novel drug discovery
candidate programs. Prior to joining Millennium, Dr. Gilman was
director, department of respiratory/allergy, immunology, inflammation
and infectious disease at Pfizer, Inc.
-- New and Extended Alliances:
* Millennium and Aventis Pharma, the pharmaceutical company of Aventis
S.A., announced the closing of agreements signifying the initiation of
a major strategic alliance between the two companies. This
partnership, the largest program of its type, covers the joint
development and commercialization of drugs for the treatment of
inflammatory diseases, joint development of new drug discovery
technologies, transfer of key elements of Millennium`s technology
platform and a purchase of an equity interest in Millennium by
Aventis. Aventis made an initial $150 million stock purchase when the
agreement closed on July 27, 2000.
-- Intellectual Property:
* Millennium was awarded 14 U.S. patents during the third quarter of
2000.
* As of September 30, 2000, Millennium owns or is the exclusive licensee
under more than 1,400 U.S. and foreign patents and patent applications,
including 121 issued U.S. patents.
-- Research and Discovery:
* Millennium announced that it had discovered ACE-related
carboxypeptidase (ACE2), a potential new target for treating
cardiovascular disease. The Company published its findings in the
August 31, 2000 issue of Circulation Research, a publication of the
American Heart Association. Millennium and Eli Lilly and Co., its
partner in heart failure research, will pursue the development of
potential drugs targeted to ACE2 for the treatment of congestive heart
failure.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employs more than 1,200 people.
Note: Millennium will host a conference call at 9:00 a.m. EST on Wednesday, October 18, 2000 to review financial results for the third quarter. This call will be broadcast simultaneously via the Internet at www.mlnm.com and will be accessible through the investor relations section of Millennium`s homepage. The call will be archived on Millennium`s site for at least two weeks.
(tables follow)
This press release contains ``forward-looking statements,`` including Millennium`s expectations of future industry conditions, strategic plans and forecasts of operational results. Various risks may cause Millennium`s actual results to differ materially, including: uncertainties about its drug discovery and clinical development processes, uncertainties about obtaining patent protection for its discoveries and about the commercial limitations imposed by patents owned or controlled by third parties; Millennium`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; uncertainties about obtaining regulatory approvals to market products and services resulting from its development efforts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of such risks and uncertainties, see the reports filed by Millennium with the Securities and Exchange Commission. Millennium disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editor`s Note: This release is also available on Millennium`s website at: http://www.mlnm.com.
MILLENNIUM PHARMACEUTICALS, INC.
SELECTED CONSOLIDATED FINANCIAL INFORMATION
habe es nun auch gefunden...
Tuesday October 17, 5:13 pm Eastern Time
Press Release
SOURCE: Millennium Pharmaceuticals, Inc.
Millennium Reports Third Quarter 2000 Financial Results
-- Exercise of Over-Allotment from Equity Offering Brings Cash Balance to Over $1.4 Billion --
CAMBRIDGE, Mass., Oct. 17 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today reported consolidated financial results for the three and nine months ended September 30, 2000.
(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
Revenue for the quarter ended September 30, 2000 was $49.8 million compared to $40.3 million for the same period in 1999. This is the first quarter that the company recognized revenue from its ground-breaking alliance with Aventis Pharma. Millennium`s corporate alliances provide the Company with substantial revenues, enabling technologies and rights that allow the Company to build upon its proprietary drug discovery and development product pipeline and technology base.
Expenditures for research and development for the quarter ended September 30, 2000 were $68.8 million versus $38.4 million for the same period in 1999. The increase is primarily due to Millennium`s investments in all aspects of research and development necessary to execute its strategy of becoming a major biopharmaceutical company. These include investments in its science and technology platform, as well as investments in development candidates and the preclinical pipeline, which were not in place in the prior period.
General and administrative expenses for the quarter ended September 30, 2000 were $12.4 million versus $8.3 million for the same period in 1999. This increase is due to the expansion of operations and infrastructure necessary to support growth at all levels of Millennium`s business.
Net operating loss, before amortization charges and debt conversion expenses, for the quarter ended September 30, 2000 was $25.9 million or $0.13 per basic and diluted share, compared to net operating loss, before amortization charges and debt conversion expenses, of $3.8 million or $0.03 per basic and diluted share for the same period in 1999. In addition, Millennium recorded amortization charges of $14.5 million for the quarter resulting from strategic acquisitions. During the quarter, Millennium paid an aggregate of $49.3 million in cash to the holders of Millennium`s convertible notes in order to induce the conversion of their notes into Millennium common stock. These conversions resulted in the retirement of $275.1 million of outstanding principal of Millennium convertible notes, and the issuance of approximately 6.5 million shares of Millennium common stock.
As of September 30, 2000, Millennium had approximately $679 million in cash, cash equivalents and marketable securities. In October, the Company raised an additional $767 million in a public offering of its common stock (including the underwriters` exercise of their over-allotment option), bringing the total cash balance as of October 17, 2000 to over $1.4 billion.
``We are on track to achieve our corporate goals for 2000, including developing the industry`s broadest emerging clinical and preclinical pipeline, enhancing productivity by addressing key bottlenecks in the drug discovery and development process, and building a world class senior leadership team,`` said Mark Levin, chief executive officer of Millennium. ``With over $1.4 billion in cash, Millennium has the resources to continue to invest in our pipeline and to enhance our downstream capabilities, moving us closer to our goal of building the biopharmaceutical company of the future.``
Third Quarter Company Highlights:
-- Stock Changes:
* The Millennium Board of Directors approved a two-for-one stock split
of its common shares effected in the form of a stock dividend.
Stockholders of record on September 27, 2000, were entitled to one
additional share of common stock for each share held on that date.
The dividend distribution date was October 4, 2000.
* Millennium announced (and completed in October 2000) a public offering
of its common stock which resulted in the Company raising $767
million. The proceeds will be used for working capital and other
corporate purposes including financing the Company`s growth,
accelerating the expansion of its technology platform and developing
products.
-- Mergers and Acquisitions:
* Millennium completed its acquisition of Cambridge Discovery Chemistry
Limited (CDC) in Cambridge, UK. CDC, renamed Millennium
Pharmaceuticals
Limited, provides the Company with the critical mass in medicinal and
computational chemistry necessary to expand the Company`s global
capacity and significantly accelerate its downstream drug discovery
efforts.
-- Senior Hires:
* Millennium announced the appointment of James A. Nash as senior vice
president of worldwide manufacturing, a newly-created position. Prior
to joining the Company, Mr. Nash was vice president of manufacturing
worldwide at Monsanto/Searle. With more than 20 years of experience
in the pharmaceutical industry, he is working with the Company`s
senior leadership team to develop and expand both small molecule and
biotherapeutic manufacturing capabilities needed to build the
biopharmaceutical company of the future.
* Michael W. Spellman, Ph.D., joined the Company as vice president of
quality assurance and quality control. Most recently, Dr. Spellman
was vice president, preclinical development at Coulter Pharmaceutical.
He brings to the Company more than 16 years experience in
biopharmaceutical drug development.
* Steven Gilman, Ph.D., joined the Company as vice president,
inflammation. Dr. Gilman brings over 20 years of experience in the
pharmaceutical and biotechnology industries, including providing
expertise for the strategic direction of novel drug discovery
candidate programs. Prior to joining Millennium, Dr. Gilman was
director, department of respiratory/allergy, immunology, inflammation
and infectious disease at Pfizer, Inc.
-- New and Extended Alliances:
* Millennium and Aventis Pharma, the pharmaceutical company of Aventis
S.A., announced the closing of agreements signifying the initiation of
a major strategic alliance between the two companies. This
partnership, the largest program of its type, covers the joint
development and commercialization of drugs for the treatment of
inflammatory diseases, joint development of new drug discovery
technologies, transfer of key elements of Millennium`s technology
platform and a purchase of an equity interest in Millennium by
Aventis. Aventis made an initial $150 million stock purchase when the
agreement closed on July 27, 2000.
-- Intellectual Property:
* Millennium was awarded 14 U.S. patents during the third quarter of
2000.
* As of September 30, 2000, Millennium owns or is the exclusive licensee
under more than 1,400 U.S. and foreign patents and patent applications,
including 121 issued U.S. patents.
-- Research and Discovery:
* Millennium announced that it had discovered ACE-related
carboxypeptidase (ACE2), a potential new target for treating
cardiovascular disease. The Company published its findings in the
August 31, 2000 issue of Circulation Research, a publication of the
American Heart Association. Millennium and Eli Lilly and Co., its
partner in heart failure research, will pursue the development of
potential drugs targeted to ACE2 for the treatment of congestive heart
failure.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employs more than 1,200 people.
Note: Millennium will host a conference call at 9:00 a.m. EST on Wednesday, October 18, 2000 to review financial results for the third quarter. This call will be broadcast simultaneously via the Internet at www.mlnm.com and will be accessible through the investor relations section of Millennium`s homepage. The call will be archived on Millennium`s site for at least two weeks.
(tables follow)
This press release contains ``forward-looking statements,`` including Millennium`s expectations of future industry conditions, strategic plans and forecasts of operational results. Various risks may cause Millennium`s actual results to differ materially, including: uncertainties about its drug discovery and clinical development processes, uncertainties about obtaining patent protection for its discoveries and about the commercial limitations imposed by patents owned or controlled by third parties; Millennium`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; uncertainties about obtaining regulatory approvals to market products and services resulting from its development efforts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of such risks and uncertainties, see the reports filed by Millennium with the Securities and Exchange Commission. Millennium disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editor`s Note: This release is also available on Millennium`s website at: http://www.mlnm.com.
MILLENNIUM PHARMACEUTICALS, INC.
SELECTED CONSOLIDATED FINANCIAL INFORMATION
das ist ja wie bei den internet-werten. money-burning.
naja vielleicht haben wir in zwei jahren die ersten
gewinnmeldungen. bei der arroganz der aktienbesitzer können die sich das wohl erlauben
naja vielleicht haben wir in zwei jahren die ersten
gewinnmeldungen. bei der arroganz der aktienbesitzer können die sich das wohl erlauben
@dosto
Lieber Dosto,
entweder Du kannst kein Englisch, oder Du bist einfach nur dumm.
Wenn ein Unternehmen der biotechnologiebranche auf über 1 Billionen $ in Cash sitzt, die Einnahmen deutlich gestiegen sind, 14 neue Patente in einem Quartal abgemeldet wurden und neue regelmässige Einnahmen aus der Cooperation mit Aventis fliessen und der erhöhte Verlust pro Aktie in diesem Quartal auf vermehrte Forschungsausgaben zurückzuführen ist, was ist daran verkehrt????
Lieber Dosto,
entweder Du kannst kein Englisch, oder Du bist einfach nur dumm.
Wenn ein Unternehmen der biotechnologiebranche auf über 1 Billionen $ in Cash sitzt, die Einnahmen deutlich gestiegen sind, 14 neue Patente in einem Quartal abgemeldet wurden und neue regelmässige Einnahmen aus der Cooperation mit Aventis fliessen und der erhöhte Verlust pro Aktie in diesem Quartal auf vermehrte Forschungsausgaben zurückzuführen ist, was ist daran verkehrt????
Lieber Captain_Blaubernd,
du solltest nicht immer gleich allen andern
Dummheit ins Gesicht klatschen solange
Du selber ganz dumme Fehler machst!
Das Unternehmen sitzt nicht auf 1 Billionen
$ in Cash sondern auf "nur" einer Milliarde.
Und die Patente wurden auch nicht abgemeldet,
sondern dem Unternehmen zugesprochen
du solltest nicht immer gleich allen andern
Dummheit ins Gesicht klatschen solange
Du selber ganz dumme Fehler machst!
Das Unternehmen sitzt nicht auf 1 Billionen
$ in Cash sondern auf "nur" einer Milliarde.
Und die Patente wurden auch nicht abgemeldet,
sondern dem Unternehmen zugesprochen
Ich war auch der Meinung, dass MLNM die Schätzungen verfehlt und der Kurs nicht zuletzt deswegen nachbörslich auf 64 $ abgegeben hat. Allerdings lese ich nun bei Reuters, dass die Ergebnisse im Rahmen der Erwartungen (First Call/Thomson Financial)liegen und wenn Reuters das sagt...
Wie auch immer - berauschend sind die Ergebnisse sicher nicht -, vielleicht läuft´s ja wie nach den ebenfalls mässigen Q2-Ergebnissen und der Wert steigt dennoch wieder - pralle Produktpipline, volle Kriegskasse usw.
Woll´n wir´s hoffen.
Ciao
Wie auch immer - berauschend sind die Ergebnisse sicher nicht -, vielleicht läuft´s ja wie nach den ebenfalls mässigen Q2-Ergebnissen und der Wert steigt dennoch wieder - pralle Produktpipline, volle Kriegskasse usw.
Woll´n wir´s hoffen.
Ciao
Ich glaube, die Q3-Zahlen werden den Kurs nicht so stark belasten, die nachbörlichen Kurse unter 70$ entstanden Kleinstorder
18.20 $ 64.5 200
17.50 $ 66 100
17.49 $ 66 100
17.49 $ 66 100
17.49 $ 66 100
17.16 $ 67 100
17.16 $ 67.125 400
17.16 $ 68 200
17.15 $ 68.75 100
16.48 $ 70.125 4700
16.39 $ 70.125 2000
16.36 $ 70 300
16.36 $ 70.0625 500
16.21 $ 71.5 100
16.08 $ 70 3800
16.08 $ 70.0625 1600
16.08 $ 70.125 900
16.08 $ 70.25 1000
16.07 $ 70.125 2800
16.07 $ 70.125 200
16.07 $ 70.125 1100
16.07 $ 70.125 400
16.07 $ 70.125 30000
16.07 $ 70.125 2200
16.07 $ 70.125 2800
16.07 $ 70.125 6300
16.07 $ 70.125 4600
16.07 $ 70.125 200
16.07 $ 70.125 100
16.07 $ 70.125 200
16.07 $ 70.125 100
16.07 $ 70.125 100
16.07 $ 70.125 800
16.07 $ 70.125 500
16.05 $ 70.125 5700
16.05 $ 70.5 800
16.04 $ 70.5 100
16.03 $ 71.3125 600
16.02 $ 70.5 800
16.01 $ 70.625 1000
16.01 $ 70.9375 100
16.01 $ 70.75 500
16.00 $ 70.125 2000
16.00 $ 70.5 700
16.00 $ 70.0625 100
16.00 $ 70.125 1000
16.00 $ 70.125 900
18.20 $ 64.5 200
17.50 $ 66 100
17.49 $ 66 100
17.49 $ 66 100
17.49 $ 66 100
17.16 $ 67 100
17.16 $ 67.125 400
17.16 $ 68 200
17.15 $ 68.75 100
16.48 $ 70.125 4700
16.39 $ 70.125 2000
16.36 $ 70 300
16.36 $ 70.0625 500
16.21 $ 71.5 100
16.08 $ 70 3800
16.08 $ 70.0625 1600
16.08 $ 70.125 900
16.08 $ 70.25 1000
16.07 $ 70.125 2800
16.07 $ 70.125 200
16.07 $ 70.125 1100
16.07 $ 70.125 400
16.07 $ 70.125 30000
16.07 $ 70.125 2200
16.07 $ 70.125 2800
16.07 $ 70.125 6300
16.07 $ 70.125 4600
16.07 $ 70.125 200
16.07 $ 70.125 100
16.07 $ 70.125 200
16.07 $ 70.125 100
16.07 $ 70.125 100
16.07 $ 70.125 800
16.07 $ 70.125 500
16.05 $ 70.125 5700
16.05 $ 70.5 800
16.04 $ 70.5 100
16.03 $ 71.3125 600
16.02 $ 70.5 800
16.01 $ 70.625 1000
16.01 $ 70.9375 100
16.01 $ 70.75 500
16.00 $ 70.125 2000
16.00 $ 70.5 700
16.00 $ 70.0625 100
16.00 $ 70.125 1000
16.00 $ 70.125 900
hatte nur Zeit den Artikel zu überfliegen.
Sehe ich es richtig, dass die Zahlen raus sind und die Ergebnisse Q3 eher schlecht sind ? Ist ein ähnlicher kurzfristiger Absturz wie bei Sepracor oder Medimmune zu befürchten?
Danke für Antworten
Sehe ich es richtig, dass die Zahlen raus sind und die Ergebnisse Q3 eher schlecht sind ? Ist ein ähnlicher kurzfristiger Absturz wie bei Sepracor oder Medimmune zu befürchten?
Danke für Antworten
Hi!
Bei Sepracor kam der Absturz durch den Umstand zustande, der in der Branche am wenigsten verziehen wird: Ein Medikament wird entweder gar nicht oder verzögert oder eben – wie bei Sepracor oder Cephalon – nur in verringertem Umfang marktreif.
Bei Medimmune war es eine Herabstufung und eine verschlechterte Prognose – das Unternehmen erwirtschaftet bereits Gewinne, da fällt das viel mehr ins Gewicht.
Bei einem Unternehmen wie Millennium und den meisten anderen Biotechs spielen die Earnings eine Nebenrolle. Kurzfristig kann es natürlich zu leichten Verunsicherungen und Kursrückgängen kommen. Die sollte man aber tunlichst zum Nachkaufen nutzen!
Bye, Nummer2
Bei Sepracor kam der Absturz durch den Umstand zustande, der in der Branche am wenigsten verziehen wird: Ein Medikament wird entweder gar nicht oder verzögert oder eben – wie bei Sepracor oder Cephalon – nur in verringertem Umfang marktreif.
Bei Medimmune war es eine Herabstufung und eine verschlechterte Prognose – das Unternehmen erwirtschaftet bereits Gewinne, da fällt das viel mehr ins Gewicht.
Bei einem Unternehmen wie Millennium und den meisten anderen Biotechs spielen die Earnings eine Nebenrolle. Kurzfristig kann es natürlich zu leichten Verunsicherungen und Kursrückgängen kommen. Die sollte man aber tunlichst zum Nachkaufen nutzen!
Bye, Nummer2
@was
muß natürlich an- statt abgemeldet heissen. Aber mal ne andere Frage: Wie würdest Du denn bitte "Milliarde" ins Englische übersetzen?
Soviel zu Deinem Kommentar.
muß natürlich an- statt abgemeldet heissen. Aber mal ne andere Frage: Wie würdest Du denn bitte "Milliarde" ins Englische übersetzen?
Soviel zu Deinem Kommentar.
was soll die ewige Streiterei denn bitte hier?
Das bringt doch alles nichts. Schreibt doch einfach Eure Meinung zu etwas was ein anderer geschrieben hat. Aber bitte ohne Beleidigungen. Wenn die Person Euch gegenübersitzen würde, dann würdet Ihr ja wohl auch nicht so beleidigend sein.
Übrigens:
Deutsch: Milliarde >> Englisch: billion
Deutsch: Billion >> Englisch: trillion
Gruß,
ricox
Das bringt doch alles nichts. Schreibt doch einfach Eure Meinung zu etwas was ein anderer geschrieben hat. Aber bitte ohne Beleidigungen. Wenn die Person Euch gegenübersitzen würde, dann würdet Ihr ja wohl auch nicht so beleidigend sein.
Übrigens:
Deutsch: Milliarde >> Englisch: billion
Deutsch: Billion >> Englisch: trillion
Gruß,
ricox
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| -0,51 | |
| +1,37 | |
| 0,00 | |
| -4,00 | |
| +1,33 | |
| -0,05 | |
| -0,12 | |
| 0,00 | |
| -0,09 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 103 | ||
| 99 | ||
| 83 | ||
| 70 | ||
| 38 | ||
| 35 | ||
| 34 | ||
| 33 | ||
| 32 |
